Effect of secondary preventive therapy on recurrence of tuberculosis in HIV-infected individuals: a systematic review

References

• WHO. Tuberculosis fact sheet no. 104. [revised 2016 Oct 16]. 2016. Available from: http://www.who.int/mediacentre/factsheets/fs104/en.
   Google Scholar
• WHO. Global tuberculosis report 2015. [revised 2016 Oct 8]. Available from: http://who.int/tb/publications/global_report/en.
   Google Scholar
• Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev. 2000;CD001363. doi: 10.1002/14651858.CD001363.
   Google Scholar
• Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2010;CD000171. doi: 10.1002/14651858.CD000171.pub3.
   Google Scholar
• AIDS by the numbers, Geneva, 2016. Available from: http://www.unaids.org/sites/default/files/media_asset/AIDS-by-the-numbers-2016_en.pdf.
   Google Scholar
• Higgins JPT, Green S (Eds). Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from: http://www.handbook.cochrane.org.
   Google Scholar
• Perriëns JH, St Louis ME, Mukadi YB, et al. Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months. N Engl J Med. 1995;332:779–784.
   PubMed Web of Science ®Google Scholar
• Haller L, Sossouhounto R, Coulibaly IM, et al. Isoniazid plus sulphadoxine-pyrimethamine can reduce morbidity of HIV-positive patients treated for tuberculosis in Africa: a controlled clinical trial. Chemotherapy. 1999;45:452–465.
   PubMed Web of Science ®Google Scholar
• Fitzgerald DW, Desvarieux M, Severe P, et al. Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial. Lancet. 2000;356:1470–1474.
   PubMed Web of Science ®Google Scholar
• Churchyard GJ, Fielding K, Charalambous S, et al. Efficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans: time to change policy?. AIDS. 2003;17:2063–2070.
   PubMed Web of Science ®Google Scholar
• WHO. Intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. [revised 2016 Oct 16]. 2011. Available from: http://www.who.int/hiv/pub/tb/9789241500708/en.
   Google Scholar
• Samandari T, Agizew TB, Nyirenda S, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;377:1588–1598.
   PubMed Web of Science ®Google Scholar
• Samandari T, Agizew TB, Nyirenda S, et al. Tuberculosis incidence after 36 months’ isoniazid prophylaxis in HIV-infected adults in Botswana: a posttrial observational analysis. AIDS. 2015;29:351–359.
   PubMed Web of Science ®Google Scholar
• Houben RMGJ, Sumner T, Grant AD, et al. Ability of preventive therapy to cure latent Mycobacterium tuberculosis infection in HIV-infected individuals in high-burden settings. Proc Natl Acad Sci USA. 2014;111:5325–5330.
   PubMed Web of Science ®Google Scholar
• Balcells ME, Thomas SL, Godfrey-Faussett P, et al. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerging Infect Dis. 2006;12:744–751.
   PubMed Web of Science ®Google Scholar
• Van Halsema CL, Fielding KL, Chihota VN, et al. Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting. AIDS. 2010;24:1051–1055.
   PubMed Web of Science ®Google Scholar
• Basu S, Maru D, Poolman E, et al. Primary and secondary tuberculosis preventive treatment in HIV clinics: simulating alternative strategies. Int J Tuberc Lung Dis. 2009;13:652–658.
   PubMed Web of Science ®Google Scholar
• Ford CB, Lin PL, Chase MR, et al. Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. Nat Genet. 2011;43:482–486.
   PubMed Web of Science ®Google Scholar
• Mills HL, Cohen T, Colijn C. Community-wide isoniazid preventive therapy drives drug-resistant tuberculosis: a model-based analysis. Sci Transl Med. 2013;5:180ra49.
   PubMed Web of Science ®Google Scholar
• Mills HL, Cohen T, Colijn C. Response to comment on “Community-wide isoniazid preventive therapy drives drug-resistant tuberculosis: a model-based analysis”. Sci Transl Med. 2013;5:204lr4.
   PubMed Web of Science ®Google Scholar
• Miranda A, Morgan M, Jamal L, et al. Impact of antiretroviral therapy on the incidence of tuberculosis: the Brazilian experience, 1995–2001. PLoS One. 2007;2:e826.
   Google Scholar
• Girardi E, Antonucci G, Vanacore P, et al. Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection. AIDS. 2000;14:1985–1991.
   PubMed Web of Science ®Google Scholar
• Santoro-Lopes G, de Pinho AMF, Harrison LH, et al. Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy. Clin Infect Dis. 2002;34:543–546.
   PubMed Web of Science ®Google Scholar
• Golub JE, Saraceni V, Cavalcante SC, et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS. 2007;21:1441–1448.
   PubMed Web of Science ®Google Scholar
• Rangaka MX, Wilkinson RJ, Boulle A, et al. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial. Lancet. 2014;384:682–690.
   PubMed Web of Science ®Google Scholar
• TEMPRANO ANRS 12136 Study Group, Danel C, Moh R, Gabillard D, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373:808–822.
   PubMed Web of Science ®Google Scholar
• Robertson K, Liner J, Meeker RB. Antiretroviral neurotoxicity. J Neurovirol. 2012;18:388–399.
   PubMed Web of Science ®Google Scholar
• Forget EJ, Menzies D. Adverse reactions to first-line antituberculosis drugs. Expert Opin Drug Saf. 2006;5:231–249.
   PubMed Web of Science ®Google Scholar
• Sonnenberg P, Murray J, Glynn JR, et al. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet. 2001;358:1687–1693.
   PubMed Web of Science ®Google Scholar
• Marx FM, Dunbar R, Enarson DA, et al. The temporal dynamics of relapse and reinfection tuberculosis after successful treatment: a retrospective cohort study. Clin Infect Dis. 2014;58:1676–1683.
   PubMed Web of Science ®Google Scholar
• Luzze H, Johnson DF, Dickman K, et al. Relapse more common than reinfection in recurrent tuberculosis 1-2 years post treatment in urban Uganda. Int J Tuberc Lung Dis. 2013;17:361–367.
   PubMed Web of Science ®Google Scholar
• Guerra-Assunção JA, Houben RMGJ, Crampin AC, et al. Recurrence due to relapse or reinfection with Mycobacterium tuberculosis: a whole-genome sequencing approach in a large, population-based cohort with a high HIV infection prevalence and active follow-up. J Infect Dis. 2015;211:1154–1163.
   PubMed Web of Science ®Google Scholar
• Unis G, Ribeiro AW, Esteves LS, et al. Tuberculosis recurrence in a high incidence setting for HIV and tuberculosis in Brazil. BMC Infect Dis. 2014;14:548
   PubMed Web of Science ®Google Scholar
• Verver S, Warren RM, Beyers N, et al. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am J Respir Crit Care Med. 2005;171:1430–1435.
   PubMed Web of Science ®Google Scholar
• Getahun H, Granich R, Sculier D, et al. Implementation of isoniazid preventive therapy for people living with HIV worldwide: barriers and solutions. AIDS. 2010;24:S57–S65.
   PubMedGoogle Scholar